{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:48:05Z","timestamp":1782175685017,"version":"3.54.5"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203528, 81972559, 82272891"],"award-info":[{"award-number":["82203528, 81972559, 82272891"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M710769, 2022TQ0072"],"award-info":[{"award-number":["2022M710769, 2022TQ0072"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08140-y","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:37:53Z","timestamp":1777563473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Applications and research progress of PET\/CT in dynamic monitoring of immunotherapy in melanoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Lilu","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujian","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoluan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengfeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"4","key":"8140_CR1","doi-asserted-by":"publisher","first-page":"578","DOI":"10.21147\/j.issn.1000-9604.2019.04.02","volume":"31","author":"Chinese guidelines for diagnosis and treatment of","year":"2019","unstructured":"Chinese guidelines for diagnosis and treatment of. melanoma 2018 (English version). Chin J Cancer Res. 2019;31(4):578\u201385.","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"8140_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8140_CR3","doi-asserted-by":"publisher","first-page":"2170095","DOI":"10.1080\/2162402X.2023.2170095","volume":"12","author":"E Orecchini","year":"2023","unstructured":"Orecchini E, Belladonna ML, Pallotta MT, et al. The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma. Oncoimmunology. 2023;12(1):2170095.","journal-title":"Oncoimmunology"},{"key":"8140_CR4","doi-asserted-by":"publisher","first-page":"123034","DOI":"10.1016\/j.biomaterials.2024.123034","volume":"316","author":"W Zhang","year":"2025","unstructured":"Zhang W, Yuan S, Zhang Z, et al. Regulating tumor cells to awaken T cell antitumor function and enhance melanoma immunotherapy. Biomaterials. 2025;316:123034.","journal-title":"Biomaterials"},{"issue":"12","key":"8140_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/s43018-024-00850-w","volume":"5","author":"L Danelli","year":"2024","unstructured":"Danelli L. Personalized neoantigen therapy for melanoma immunotherapy. Nat Cancer. 2024;5(12):1783.","journal-title":"Nat Cancer"},{"issue":"8","key":"8140_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"8140_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138.","journal-title":"Ann Oncol"},{"issue":"8","key":"8140_CR8","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908\u201318.","journal-title":"Lancet Oncol"},{"key":"8140_CR9","doi-asserted-by":"publisher","first-page":"882471","DOI":"10.3389\/fimmu.2022.882471","volume":"13","author":"L Si","year":"2022","unstructured":"Si L, Zhang X, Shu Y, et al. Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study. Front Immunol. 2022;13:882471.","journal-title":"Front Immunol"},{"issue":"4","key":"8140_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384.","journal-title":"Lancet Oncol"},{"issue":"1","key":"8140_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"key":"8140_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","volume":"82","author":"MV Heppt","year":"2017","unstructured":"Heppt MV, Heinzerling L, K\u00e4hler KC, et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer. 2017;82:56\u201365.","journal-title":"Eur J Cancer"},{"key":"8140_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ctrv.2017.08.009","volume":"60","author":"MV Heppt","year":"2017","unstructured":"Heppt MV, Steeb T, Schlager JG, et al. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. Cancer Treat Rev. 2017;60:44\u201352.","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"8140_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"key":"8140_CR15","doi-asserted-by":"crossref","unstructured":"Hossain SM, Eccles MR. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance. Int J Mol Sci. 2023;24(2).","DOI":"10.3390\/ijms24021601"},{"issue":"12","key":"8140_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/17512433.2024.2431513","volume":"17","author":"J Justice","year":"2024","unstructured":"Justice J, Kankaria RA, Johnson DB. Immune checkpoint inhibition of metastatic melanoma: achieving high efficacy in the face of high toxicity. Expert Rev Clin Pharmacol. 2024;17(12):1115\u201325.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"8140_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","volume":"17","author":"DG Coit","year":"2019","unstructured":"Coit DG, Thompson JA, Albertini MR, et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(4):367\u2013402.","journal-title":"J Natl Compr Canc Netw"},{"key":"8140_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-030-02505-2_8","volume":"995","author":"Y Tian","year":"2018","unstructured":"Tian Y, Abu-Sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Hepatitis. Adv Exp Med Biol. 2018;995:159\u201364.","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"8140_CR19","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","volume":"58","author":"SY Cho","year":"2017","unstructured":"Cho SY, Lipson EJ, Im H, et al. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point (18)F-FDG PET\/CT Imaging in Patients with Advanced Melanoma. J Nucl Med. 2017;58(9):1421\u20138.","journal-title":"J Nucl Med"},{"issue":"3","key":"8140_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2967\/jnumed.118.213652","volume":"60","author":"K Ito","year":"2019","unstructured":"Ito K, Teng R, Sch\u00f6der H, et al. (18)F-FDG PET\/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. J Nucl Med. 2019;60(3):335\u201341.","journal-title":"J Nucl Med"},{"issue":"2","key":"8140_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.23736\/S1824-4785.20.03251-3","volume":"64","author":"A Castello","year":"2020","unstructured":"Castello A, Lopci E. Update on tumor metabolism and patterns of response to immunotherapy. Q J Nucl Med Mol Imaging. 2020;64(2):175\u201385.","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"8140_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1200\/EDBK_200643","volume":"38","author":"E Borcoman","year":"2018","unstructured":"Borcoman E, Nandikolla A, Long G, Goel S, Le Tourneau C. Patterns of Response and Progression to Immunotherapy. Am Soc Clin Oncol Educ Book. 2018;38:169\u201378.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"8140_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21037\/jtd.2018.12.47","volume":"11","author":"CE Onesti","year":"2019","unstructured":"Onesti CE, Fr\u00e8res P, Jerusalem G. Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients\u2019 treatment. J Thorac Dis. 2019;11(1):35\u20138.","journal-title":"J Thorac Dis"},{"issue":"8","key":"8140_CR24","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1\/PD-L1. Clin Cancer Res. 2017;23(8):1920\u20138.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"8140_CR25","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017;23(15):4242\u201350.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"8140_CR26","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","volume":"28","author":"E Sa\u00e2da-Bouzid","year":"2017","unstructured":"Sa\u00e2da-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605\u201311.","journal-title":"Ann Oncol"},{"issue":"3","key":"8140_CR27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1158\/1078-0432.CCR-18-1390","volume":"25","author":"G Lo Russo","year":"2019","unstructured":"Lo Russo G, Moro M, Sommariva M, et al. Antibody-Fc\/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1\/PD-L1 Blockade. Clin Cancer Res. 2019;25(3):989\u201399.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"8140_CR28","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/1078-0432.CCR-19-2226","volume":"26","author":"I Matos","year":"2020","unstructured":"Matos I, Martin-Liberal J, Garc\u00eda-Ruiz A, et al. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. Clin Cancer Res. 2020;26(8):1846\u201355.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8140_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaoncol.2020.5582","volume":"7","author":"I Matos","year":"2021","unstructured":"Matos I, Garralda E. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy. JAMA Oncol. 2021;7(1):136\u20137.","journal-title":"JAMA Oncol"},{"issue":"11","key":"8140_CR30","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","volume":"4","author":"R Ferrara","year":"2018","unstructured":"Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1\/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018;4(11):1543\u201352.","journal-title":"JAMA Oncol"},{"issue":"6","key":"8140_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2967\/jnumed.119.237768","volume":"61","author":"A Castello","year":"2020","unstructured":"Castello A, Rossi S, Mazziotti E, Toschi L, Lopci E. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of (18)F-FDG PET\/CT. J Nucl Med. 2020;61(6):821\u20136.","journal-title":"J Nucl Med"},{"key":"8140_CR32","doi-asserted-by":"publisher","first-page":"566297","DOI":"10.3389\/fonc.2020.566297","volume":"10","author":"O Humbert","year":"2020","unstructured":"Humbert O, Chardin D. Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy. Front Oncol. 2020;10:566297.","journal-title":"Front Oncol"},{"issue":"5","key":"8140_CR33","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1007\/s00259-019-04573-4","volume":"47","author":"O Humbert","year":"2020","unstructured":"Humbert O, Cadour N, Paquet M, et al. (18)FDG PET\/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging. 2020;47(5):1158\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8140_CR34","doi-asserted-by":"publisher","first-page":"e940954","DOI":"10.12659\/AJCR.940954","volume":"24","author":"AM Cuevas Velazquez","year":"2023","unstructured":"Cuevas Velazquez AM, Ng WL, Calder\u00f3n Mart\u00ednez EJ, Yeruva SLH. Pseudo-Progression of Melanoma Treated with Nivolumab\/Ipilimumab: A Case Report. Am J Case Rep. 2023;24:e940954.","journal-title":"Am J Case Rep"},{"issue":"5","key":"8140_CR35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","volume":"22","author":"SM Swetter","year":"2024","unstructured":"Swetter SM, Johnson D, Albertini MR, et al. NCCN Guidelines\u00ae Insights: Melanoma: Cutaneous, Version 2.2024. J Natl Compr Canc Netw. 2024;22(5):290\u20138.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"8140_CR36","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","volume":"36","author":"T Amaral","year":"2025","unstructured":"Amaral T, Ottaviano M, Arance A, et al. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36(1):10\u201330.","journal-title":"Ann Oncol"},{"key":"8140_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jcm10215160","volume":"10","author":"E Lopci","year":"2021","unstructured":"Lopci E. Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET\/CT in Metastatic Melanomas and Lung Cancer. J Clin Med. 2021;10:21.","journal-title":"J Clin Med"},{"issue":"1","key":"8140_CR38","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(1):S122\u201350.","journal-title":"J Nucl Med"},{"issue":"3","key":"8140_CR39","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","volume":"45","author":"H Anwar","year":"2018","unstructured":"Anwar H, Sachpekidis C, Winkler J, et al. Absolute number of new lesions on (18)F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45(3):376\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"8140_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13550-019-0473-1","volume":"9","author":"L Goldfarb","year":"2019","unstructured":"Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9(1):8.","journal-title":"EJNMMI Res"},{"issue":"3","key":"8140_CR41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2967\/jnumed.118.213652","volume":"60","author":"K Ito","year":"2019","unstructured":"Ito K, Teng R, Sch\u00f6der H, et al. (18)F-FDG PET\/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. J Nucl Med. 2019;60(3):335\u201341.","journal-title":"J Nucl Med"},{"issue":"13","key":"8140_CR42","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35(13):1773\u201382.","journal-title":"Eur J Cancer"},{"issue":"9","key":"8140_CR43","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s00259-023-06247-8","volume":"50","author":"N Ayati","year":"2023","unstructured":"Ayati N, Jamshidi-Araghi Z, Hoellwerth M, et al. Predictive value and accuracy of [(18)F]FDG PET\/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma. Eur J Nucl Med Mol Imaging. 2023;50(9):2715\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"8140_CR44","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1007\/s00259-023-06243-y","volume":"50","author":"C Sachpekidis","year":"2023","unstructured":"Sachpekidis C, Weru V, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. The prognostic value of [(18)F]FDG PET\/CT based response monitoring in metastatic melanoma patients undergoing immunotherapy: comparison of different metabolic criteria. Eur J Nucl Med Mol Imaging. 2023;50(9):2699\u2013714.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8140_CR45","doi-asserted-by":"crossref","unstructured":"Rivas A, Delyon J, Martineau A et al. 18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. Cancers (Basel). 2022;14(13).","DOI":"10.3390\/cancers14133190"},{"issue":"8","key":"8140_CR46","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00259-018-3972-9","volume":"45","author":"C Sachpekidis","year":"2018","unstructured":"Sachpekidis C, Anwar H, Winkler J, et al. The role of interim (18)F-FDG PET\/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2018;45(8):1289\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"8140_CR47","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s00259-021-05650-3","volume":"49","author":"N Hribernik","year":"2022","unstructured":"Hribernik N, Huff DT, Studen A, et al. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. Eur J Nucl Med Mol Imaging. 2022;49(6):1857\u201369.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"8140_CR48","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11604-024-01554-y","volume":"42","author":"BM Gideonse","year":"2024","unstructured":"Gideonse BM, Birkeland M, Vilstrup MH, et al. Organ-specific accuracy of [(18)F]FDG-PET\/CT in identifying immune-related adverse events in patients with high-risk melanoma treated with adjuvant immune checkpoint inhibitor. Jpn J Radiol. 2024;42(7):753\u201364.","journal-title":"Jpn J Radiol"},{"issue":"4","key":"8140_CR49","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/08465371251334929","volume":"76","author":"V Murad","year":"2025","unstructured":"Murad V, Metser U, Kohan A, Murad S, Veit-Haibach P, Ortega C. (18)F-FDG PET\/CT for the Detection of Immune-Related Adverse Events in Patients With Metastatic Melanoma Receiving Immunotherapy. Can Assoc Radiol J. 2025;76(4):720\u201330.","journal-title":"Can Assoc Radiol J"},{"issue":"3","key":"8140_CR50","doi-asserted-by":"publisher","first-page":"245","DOI":"10.23736\/S1824-4785.22.03453-7","volume":"66","author":"C Sachpekidis","year":"2022","unstructured":"Sachpekidis C, Hassel JC, Dimitrakopoulou-Strauss A. Adverse effects under immune checkpoint inhibitors on [18F]FDG PET\/CT imaging. Q J Nucl Med Mol Imaging. 2022;66(3):245\u201354.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"11","key":"8140_CR51","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s11912-023-01453-x","volume":"25","author":"MC Sergi","year":"2023","unstructured":"Sergi MC, Filoni E, Triggiano G, et al. Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment. Curr Oncol Rep. 2023;25(11):1247\u201358.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"8140_CR52","doi-asserted-by":"publisher","first-page":"105813","DOI":"10.5306\/wjco.v16.i6.105813","volume":"16","author":"L Tang","year":"2025","unstructured":"Tang L, Wang Y, Lei H, et al. Clinical characteristics and prognostic factors in patients with malignant melanoma: A Chinese prospective cohort study. World J Clin Oncol. 2025;16(6):105813.","journal-title":"World J Clin Oncol"},{"issue":"1","key":"8140_CR53","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/CMR.0000000000000925","volume":"34","author":"Y Cao","year":"2024","unstructured":"Cao Y, Afzal MZ, Gutmann EJ, Shirai K. Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors. Melanoma Res. 2024;34(1):70\u20135.","journal-title":"Melanoma Res"},{"issue":"3","key":"8140_CR54","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2478\/raon-2024-0045","volume":"58","author":"N Hribernik","year":"2024","unstructured":"Hribernik N, Strasek K, Huff DT, et al. Role of quantitative imaging biomarkers in an early FDG-PET\/CT for detection of immune-related adverse events in melanoma patients: a prospective study. Radiol Oncol. 2024;58(3):335\u201347.","journal-title":"Radiol Oncol"},{"issue":"1","key":"8140_CR55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s40644-024-00774-9","volume":"24","author":"G Santo","year":"2024","unstructured":"Santo G, Cuc\u00e8 M, Restuccia A, et al. Immune-related [(18)F]FDG PET findings in patients undergoing checkpoint inhibitors treatment: correlation with clinical adverse events and prognostic implications. Cancer Imaging. 2024;24(1):125.","journal-title":"Cancer Imaging"},{"issue":"12","key":"8140_CR56","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s00259-020-04792-0","volume":"47","author":"R Nakamoto","year":"2020","unstructured":"Nakamoto R, Zaba LC, Rosenberg J, et al. Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. Eur J Nucl Med Mol Imaging. 2020;47(12):2787\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"8140_CR57","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1007\/s00259-020-04815-w","volume":"47","author":"A Iravani","year":"2020","unstructured":"Iravani A, Osman MM, Weppler AM, et al. FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Eur J Nucl Med Mol Imaging. 2020;47(12):2776\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"8140_CR58","doi-asserted-by":"publisher","first-page":"e221180","DOI":"10.1148\/radiol.221180","volume":"307","author":"A Iravani","year":"2023","unstructured":"Iravani A, Wallace R, Lo SN, et al. FDG PET\/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab. Radiology. 2023;307(3):e221180.","journal-title":"Radiology"},{"issue":"4","key":"8140_CR59","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1097\/RLU.0000000000002453","volume":"44","author":"T Nobashi","year":"2019","unstructured":"Nobashi T, Baratto L, Reddy SA, et al. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET\/CT. Clin Nucl Med. 2019;44(4):e272\u20139.","journal-title":"Clin Nucl Med"},{"issue":"9","key":"8140_CR60","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1158\/1078-0432.CCR-23-2390","volume":"30","author":"TM Anderson","year":"2024","unstructured":"Anderson TM, Chang BH, Huang AC, et al. FDG PET\/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma. Clin Cancer Res. 2024;30(9):1758\u201367.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"8140_CR61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/RLU.0000000000002921","volume":"45","author":"A Annovazzi","year":"2020","unstructured":"Annovazzi A, Vari S, Giannarelli D, et al. Comparison of 18F-FDG PET\/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. Clin Nucl Med. 2020;45(3):187\u201394.","journal-title":"Clin Nucl Med"},{"issue":"10","key":"8140_CR62","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00259-020-04757-3","volume":"47","author":"R Seban","year":"2020","unstructured":"Seban R, Moya-Plana A, Antonios L, et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging. 2020;47(10):2301\u201312.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"8140_CR63","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1007\/s00259-020-05137-7","volume":"48","author":"C Sachpekidis","year":"2021","unstructured":"Sachpekidis C, Kopp-Schneider A, Pan L, et al. Interim [(18)F]FDG PET\/CT can predict response to anti-PD-1 treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2021;48(6):1932\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"8140_CR64","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00259-019-04411-7","volume":"46","author":"R Seban","year":"2019","unstructured":"Seban R, Nemer JS, Marabelle A, et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46(11):2298\u2013310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8140_CR65","doi-asserted-by":"crossref","unstructured":"Seith F, Forschner A, Weide B et al. Is there a link between very early changes of primary and secondary lymphoid organs in (18)F-FDG-PET\/MRI and treatment response to checkpoint inhibitor therapy? J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-000656"},{"issue":"8","key":"8140_CR66","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1007\/s00259-020-05103-3","volume":"48","author":"K Prigent","year":"2021","unstructured":"Prigent K, Lasnon C, Ezine E, et al. Assessing immune organs on (18)F-FDG PET\/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. Eur J Nucl Med Mol Imaging. 2021;48(8):2573\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8140_CR67","doi-asserted-by":"crossref","unstructured":"Borch TH, Andersen R, Hendel HW, Madsen K, Ellebaek E, Marie Svane I. Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes. J Immunother Cancer. 2025;13(2).","DOI":"10.1136\/jitc-2024-010575"},{"issue":"11","key":"8140_CR68","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2967\/jnumed.120.248823","volume":"61","author":"A Iravani","year":"2020","unstructured":"Iravani A, Hicks RJ. Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents. J Nucl Med. 2020;61(11):1553\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"8140_CR69","doi-asserted-by":"publisher","first-page":"512","DOI":"10.2967\/jnumed.119.229781","volume":"61","author":"N Pandit-Taskar","year":"2020","unstructured":"Pandit-Taskar N, Postow MA, Hellmann MD, et al. First-in-Humans Imaging with (89)Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. J Nucl Med. 2020;61(4):512\u20139.","journal-title":"J Nucl Med"},{"issue":"8","key":"8140_CR70","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1084\/jem.20161950","volume":"214","author":"M Rashidian","year":"2017","unstructured":"Rashidian M, Ingram JR, Dougan M, et al. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017;214(8):2243\u201355.","journal-title":"J Exp Med"},{"issue":"12","key":"8140_CR71","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/s41591-018-0255-8","volume":"24","author":"F Bensch","year":"2018","unstructured":"Bensch F, van der Veen EL, Lub-De Hooge MN, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24(12):1852\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"8140_CR72","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1078-0432.CCR-18-2407","volume":"25","author":"BM Larimer","year":"2019","unstructured":"Larimer BM, Bloch E, Nesti S, et al. The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clin Cancer Res. 2019;25(4):1196\u2013205.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"8140_CR73","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1158\/0008-5472.CAN-16-2953","volume":"77","author":"JA Ronald","year":"2017","unstructured":"Ronald JA, Kim B, Gowrishankar G, et al. A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res. 2017;77(11):2893\u2013902.","journal-title":"Cancer Res"},{"issue":"1","key":"8140_CR74","doi-asserted-by":"publisher","first-page":"e194003","DOI":"10.1148\/rycan.2019194003","volume":"1","author":"DK Hathi","year":"2019","unstructured":"Hathi DK, Jones EF. (68)Ga FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer. Radiol Imaging Cancer. 2019;1(1):e194003.","journal-title":"Radiol Imaging Cancer"},{"key":"8140_CR75","doi-asserted-by":"crossref","unstructured":"Miedema IHC, Pouw JEE, Kwakman A et al. Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by (18)F-BMS986-192 PET: pooled analysis of data from four solid tumor types. J Immunother Cancer. 2024;12(6).","DOI":"10.1136\/jitc-2024-008899"},{"issue":"2","key":"8140_CR76","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00259-022-05986-4","volume":"50","author":"C Jiang","year":"2023","unstructured":"Jiang C, Tian Q, Xu X, et al. Enhanced antitumor immune responses via a new agent [(131)I]-labeled dual-target immunosuppressant. Eur J Nucl Med Mol Imaging. 2023;50(2):275\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"8140_CR77","first-page":"720","volume":"63","author":"MD Farwell","year":"2022","unstructured":"Farwell MD, Gamache RF, Babazada H, et al. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of (89)Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody. J Nucl Med. 2022;63(5):720\u20136.","journal-title":"J Nucl Med"},{"issue":"4","key":"8140_CR78","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s00259-024-06999-x","volume":"52","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zheng M, Zhao J, et al. Human dose-escalation study of PET imaging CD8(+) T-cell infiltration in solid malignancies with [(68)Ga]Ga -NODAGA-SNA006. Eur J Nucl Med Mol Imaging. 2025;52(4):1332\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"8140_CR79","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.2967\/jnumed.124.267529","volume":"65","author":"Q Liu","year":"2024","unstructured":"Liu Q, Xu X, Yang Z, et al. Granzyme B PET\/CT Imaging Evaluates Early Response to Immunotherapy in Gastric Cancer. J Nucl Med. 2024;65(11):1695\u2013701.","journal-title":"J Nucl Med"},{"issue":"1","key":"8140_CR80","doi-asserted-by":"publisher","first-page":"8791","DOI":"10.1038\/s41467-024-53197-2","volume":"15","author":"X Shen","year":"2024","unstructured":"Shen X, Zhou H, Zhou X, et al. (68)Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1\/2 clinical trial. Nat Commun. 2024;15(1):8791.","journal-title":"Nat Commun"},{"issue":"12","key":"8140_CR81","first-page":"1869","volume":"65","author":"J Levi","year":"2024","unstructured":"Levi J, Das M, Vasanawala MS, et al. [(18)F]F-AraG Uptake in Vertebral Bone Marrow May Predict Survival in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-(L)1 Immunotherapy. J Nucl Med. 2024;65(12):1869\u201375.","journal-title":"J Nucl Med"},{"issue":"7","key":"8140_CR82","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2967\/jnumed.121.262426","volume":"63","author":"CE Mona","year":"2022","unstructured":"Mona CE, Benz MR, Hikmat F, et al. Correlation of (68)Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study. J Nucl Med. 2022;63(7):1021\u20136.","journal-title":"J Nucl Med"},{"issue":"20","key":"8140_CR83","doi-asserted-by":"publisher","first-page":"9395","DOI":"10.7150\/thno.48392","volume":"10","author":"A R\u00fchle","year":"2020","unstructured":"R\u00fchle A, Grosu A, Wiedenmann N, et al. Hypoxia dynamics on FMISO-PET in combination with PD-1\/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation. Theranostics. 2020;10(20):9395\u2013406.","journal-title":"Theranostics"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08140-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08140-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:04:09Z","timestamp":1782173049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08140-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8140"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08140-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a literature review and does not involve human or animal subjects; therefore, ethics approval and participant consent are not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"797"}}